These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

398 related items for PubMed ID: 18495286

  • 1. Long-acting insulin analogues versus NPH human insulin in type 2 diabetes: a meta-analysis.
    Monami M, Marchionni N, Mannucci E.
    Diabetes Res Clin Pract; 2008 Aug; 81(2):184-9. PubMed ID: 18495286
    [Abstract] [Full Text] [Related]

  • 2. Safety and efficacy of glargine compared with NPH insulin for the treatment of Type 2 diabetes: a meta-analysis of randomized controlled trials.
    Bazzano LA, Lee LJ, Shi L, Reynolds K, Jackson JA, Fonseca V.
    Diabet Med; 2008 Aug; 25(8):924-32. PubMed ID: 18959605
    [Abstract] [Full Text] [Related]

  • 3. Intermediate and long-acting insulins: a review of NPH insulin, insulin glargine and insulin detemir.
    Peterson GE.
    Curr Med Res Opin; 2006 Dec; 22(12):2613-9. PubMed ID: 17166343
    [Abstract] [Full Text] [Related]

  • 4. Less weight gain and hypoglycaemia with once-daily insulin detemir than NPH insulin in intensification of insulin therapy in overweight Type 2 diabetes patients: the PREDICTIVE BMI clinical trial.
    Fajardo Montañana C, Hernández Herrero C, Rivas Fernández M.
    Diabet Med; 2008 Aug; 25(8):916-23. PubMed ID: 18959604
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. [Costs of antihyperglycemic drugs and consumables and treatment satisfaction in patients with type 2 diabetes. Results of the health care research study LIVE-DE (long-acting insulin glargine compared with NPH insulin in Germany)].
    Hauner H, Kohlmann T, Landgraf W, Holle R, Pirk O, Scholten T.
    Dtsch Med Wochenschr; 2009 Jun; 134(23):1207-13. PubMed ID: 19472091
    [Abstract] [Full Text] [Related]

  • 7. Basal insulin switch from NPH to glargine in children and adolescents with type 1 diabetes.
    Päivärinta M, Tapanainen P, Veijola R.
    Pediatr Diabetes; 2008 Jun; 9(3 Pt 2):83-90. PubMed ID: 18221431
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Lower severe hypoglycemia risk: insulin glargine versus NPH insulin in type 2 diabetes.
    Dailey G, Strange P.
    Am J Manag Care; 2008 Jan; 14(1):25-30. PubMed ID: 18197742
    [Abstract] [Full Text] [Related]

  • 10. The role of new basal insulin analogues in the initiation and optimisation of insulin therapy in type 2 diabetes.
    Baxter MA.
    Acta Diabetol; 2008 Dec; 45(4):253-68. PubMed ID: 18766296
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus.
    Horvath K, Jeitler K, Berghold A, Ebrahim SH, Gratzer TW, Plank J, Kaiser T, Pieber TR, Siebenhofer A.
    Cochrane Database Syst Rev; 2007 Apr 18; (2):CD005613. PubMed ID: 17443605
    [Abstract] [Full Text] [Related]

  • 14. Long-acting insulin analogues vs. NPH human insulin in type 1 diabetes. A meta-analysis.
    Monami M, Marchionni N, Mannucci E.
    Diabetes Obes Metab; 2009 Apr 18; 11(4):372-8. PubMed ID: 19267715
    [Abstract] [Full Text] [Related]

  • 15. Insulin glargine: a long-acting insulin for diabetes mellitus.
    Garces K.
    Issues Emerg Health Technol; 2003 Nov 18; (52):1-4. PubMed ID: 14626260
    [Abstract] [Full Text] [Related]

  • 16. Insulin analogues in the management of diabetes.
    Vázquez-Carrera M, Silvestre JS.
    Methods Find Exp Clin Pharmacol; 2004 Nov 18; 26(6):445-61. PubMed ID: 15349139
    [Abstract] [Full Text] [Related]

  • 17. [Insulin analogues: place of detemir (levemir)].
    Dorchy H, Sternon J.
    Rev Med Brux; 2006 Nov 18; 27(2):89-94. PubMed ID: 16736846
    [Abstract] [Full Text] [Related]

  • 18. Differences in hypoglycemia event rates and associated cost-consequence in patients initiated on long-acting and intermediate-acting insulin products.
    Bullano MF, Al-Zakwani IS, Fisher MD, Menditto L, Willey VJ.
    Curr Med Res Opin; 2005 Feb 18; 21(2):291-8. PubMed ID: 15802000
    [Abstract] [Full Text] [Related]

  • 19. Insulin detemir: new drug. A second long-acting insulin analogue: many uncertainties, few advantages.
    Prescrire Int; 2006 Oct 18; 15(85):163-7. PubMed ID: 17121210
    [Abstract] [Full Text] [Related]

  • 20. Insulin glargine for type 2 diabetes.
    Hemraj F, Garces K.
    Issues Emerg Health Technol; 2004 Aug 18; (59):1-4. PubMed ID: 15311441
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.